Dublin listed Amryt Pharma has filed an application with the US Securities and Exchange Commission (SEC) seeking to have its shares listed for trading on the Nasdaq stock exchange.
But the biopharmaceutical company, which develops and commercialises new therapeutics to treat patients suffering from serious and life-threatening rare diseases, is not proposing to raise funds through the listing by selling new shares.
The company said the registration is subject to ongoing review by the SEC, and the proposed listing by way of American Depository Shares is subject to approval.
The firm reported combined revenues of $154.1m last year, up 13% on the previous year.
The results included contributions from Aegerion Pharmaceuticals which Amryt bought last September.
It is understood the US listing is aimed at widening the coverage of Amyrt's business across the world.
